Dr. Datasons Labs Ltd - Stock Valuation and Financial Performance

BSE: 533412 | NSE: DRDATSONS | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Dr. Datasons Labs

M-Cap below 100cr DeciZen not available

Dr. Datasons Labs stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
68.9 Cr.
52-wk low:
6.3
52-wk high:
6.3

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Dr. Datasons Labs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14TTM
ROCE % 0%0%0%33.2%20.7%23.8%23.9%13.2%7.8%2.9%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 00021.990.1162320480521421507
Sales YoY Gr.-NANANA311.9%79.4%98.1%49.9%8.5%-19.2%-
Adj EPS 00011.610.325.547.829.220.8-1.5-0.6
YoY Gr.-NANANA-11%147.4%87.4%-38.9%-28.8%-107.3%-
BVPS (₹) 00-21.921.424.986.2177.4251.9222.8128.955.5
Adj Net
Profit
0002.35.114.836.240.628.9-4.8-6
Cash Flow from Ops. 000.1-2.3-21.90.5-45.8-45.839.7135-
Debt/CF from Ops. 004.1-5.3-1.7110.1-3-6.513.93.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA36.1%9.6%-19.2%
Adj EPS NA-168.2%-131.7%-107.3%
BVPSNA39%-10.1%-42.2%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'05Mar'06Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14TTM
Return on
Equity %
000108.761.547.539.416.88.8-1.3-0.6
Op. Profit
Mgn %
00021.612.118.122.22220.313.53.9
Net Profit
Mgn %
00010.65.79.111.38.55.6-1.1-1.2
Debt to
Equity
00-24.82.93.11.210.91.81.2-
Working Cap
Days
000140128146148202289499801
Cash Conv.
Cycle
0001261241201371791872604

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Dr. Datasons Labs Ltd.

Standalone Consolidated
TTM EPS (₹) -0.6 0
TTM Sales (₹ Cr.) 507 421
BVPS (₹.) 55.5 55.4
Reserves (₹ Cr.) 498 498
P/BV 0.11 0.11
PE 0.00 142.65
From the Market
52 Week Low / High (₹) 6.29 / 6.29
All Time Low / High (₹) 5.48 / 850.70
Market Cap (₹ Cr.) 68.9
Equity (₹ Cr.) 109.6
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Dr. Datasons Labs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *94.4094.1990.4290.3290.2089.8787.7486.730.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Dr. Datasons Labs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14
Sales021.8890.13161.67320.26479.96520.76421.05
Operating Expenses 017.1679.24132.40249.63374.52414.93364.17
Manufacturing Costs00.412.164.075.359.379.616.27
Material Costs016.0873.62123.02232.70353.20386.88349.91
Employee Cost 00.121.571.573.544.505.314.21
Other Costs 00.561.893.748.047.4513.133.78
Operating Profit 04.7110.9029.2770.63105.44105.8356.89
Operating Profit Margin (%) -21.5%12.1%18.1%22.1%22.0%20.3%13.5%
Other Income 000.010.530.192.364.717.87
Interest 00.782.586.0713.6529.0942.6843.03
Depreciation 00.230.520.882.5815.6720.2220.44
Exceptional Items 000000-44.860
Profit Before Tax 03.717.8122.8554.5963.052.771.29
Tax 01.392.717.7818.5822.022.220.62
Profit After Tax 02.325.1115.0836.0141.030.550.67
PAT Margin (%) -10.6%5.7%9.3%11.2%8.5%0.1%0.2%
Adjusted EPS (₹)0.011.610.326.147.529.50.40.2
Dividend Payout Ratio (%)0%0%0%0%0%0%25%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14

Equity and Liabilities

Shareholders Fund -0.024.2912.3149.77134.39349.80309.47407.87
Share Capital 0.0124.955.787.5813.8913.8931.66
Reserves -0.032.297.3644126.81335.91295.58376.21
Minority Interest00000000
Debt0.5412.4437.6359.69138.85298.59550.03375.12
Long Term Debt0.5412.4437.6359.6957.15101.68358.81167
Short Term Debt000081.70196.91191.22208.12
Trade Payables00015.60-6.0340.07158.86312.46
Others Liabilities 0.2010.8710.769.6927.6829.4937.72167.45
Total Liabilities 0.7227.6060.70134.76294.88717.951,056.081,262.89

Fixed Assets

Gross Block010.9713.9548.5574.55233.73248.55248.82
Accumulated Depreciation00.230.741.624.2119.8740.0960.53
Net Fixed Assets010.7413.2046.9370.35213.85208.46188.29
CWIP 0.67004.2046.68144.24164.09179.01
Investments 00.050.050.050.050.782.40212.78
Inventories02.7915.3436.0482.37137.52166.49185.53
Trade Receivables012.3130.9243.3090.46200.58272.37365.91
Cash Equivalents 0.010.080.730.750.674.15212.331.22
Others Assets0.031.630.463.494.3016.8429.93130.14
Total Assets 0.7227.6060.70134.76294.88717.951,056.081,262.89

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14
Cash Flow From Operating Activity 0.13-2.34-21.930.54-45.81-45.8339.67134.66
PBT 03.717.8122.8554.5963.052.771.29
Adjustment 01.363.066.8716.1243.03107.4563.45
Changes in Working Capital 0.13-7.4-32.21-26.81-114.53-131.47-68.8869.94
Tax Paid 00-0.61-2.37-2-20.44-1.67-0.02
Cash Flow From Investing Activity -0.67-10.70-2.98-38.76-68.41-255.77-36.02-225.57
Capex -0.67-10.30-2.98-38.80-68.48-256.73-34.68-15.19
Net Investments 0-0.05000-0.73-1.62-210.38
Others 0-0.3500.050.071.690.280.01
Cash Flow From Financing Activity 0.5513.1125.5638.24114.14305.08204.54-120.20
Net Proceeds from Shares 0.011.992.9522.3248.60174.39-0.8797.72
Net Proceeds from Borrowing 000037.1744.53257.13-191.81
Interest Paid 0-0.78-2.58-6.04-13.61-29.05-42.65-43.01
Dividend Paid 00000000
Others 0.5411.9025.1921.9641.98115.21-9.0816.90
Net Cash Flow 0.010.070.650.03-0.093.48208.18-211.11
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14
Ratios
ROE (%)N/A108.761.5348.5739.1116.950.170.19
ROCE (%)N/A52.0431.1836.2935.6619.996.035.03
Asset Turnover Ratio01.552.041.651.490.950.590.36
PAT to CFO Conversion(x)INF-1.01-4.290.04-1.27-1.1272.13200.99
Working Capital Days
Receivable Days0205888476111166277
Inventory Days04737586784107153
Payable Days0002381894246

Dr. Datasons Labs Ltd Stock News

Dr. Datasons Labs Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Dr. Datasons Labs on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Dr. Datasons Labs stood at ₹68.93.
The latest P/E ratio of Dr. Datasons Labs as of 01-Jan-1970 05:30 is 0.00.
The latest P/B ratio of Dr. Datasons Labs as of 01-Jan-1970 05:30 is 0.11.
The 52-week high of Dr. Datasons Labs is ₹6.29 and the 52-week low is ₹6.29.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dr. Datasons Labs is ₹507.4 ( Cr.) .

About Dr. Datasons Labs Ltd

Aanjaneya Lifecare was born of a vision. Incorporated in 2006 it has evolved into a leading research based integrated pharmaceutical company with established research, manufacturing and marketing capabilities.  It is R&D focused, has a multi product portfolio with state of the art manufacturing facilities, and is set to become a marketing conglomerate across the globe. Aanjaneya has created a name for itself in the manufacture of bulk actives and finished dosage forms its area of core competence. Driven by a top class team of managers and motivators this organization is counted as one of the most professional companies of India and a preferred place for top innovators and mangers to join the bandwagon of the globally significant Indian Pharma industry.

Its research team has proved itself to be a power house of innovation by filing many international patents for oncological therapeutics. The company is constantly working to broaden the pipeline of products and to make an impact in the international markets. The company reaches out to all the significant markets across South Asia and their distribution partners are highly dynamic, working to deliver the ideas and products to the market at great speed. Its contract manufacturing of these products provides great value to major marketing companies of the world working in India and the Europe. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the company is entering the high value specialty branded generic formulations segment, with a global marketing network. Last but not the least; the company is deeply committed to alleviate human suffering in the most ethical manner.

Patents

  • The company has received 5 product patents from Indian Patent office for Trans- dermal delivery system for Hormone Replacement Therapy.
  • The company has filed 3 world patents for improved and non infringing route of Synthesis of Anti Cancer Drugs Gemcitabine Hcl, Docetavel Anhydrous and Capecitabine.
  • The company has filed a World Patent for Extraction of Quinine hydrochloride directly from Quinine base using water as solvent.
  • The company has filed world patents for lozenges in therapeutic segments like Anti-smoking, Appetite enhancer, Irregular Bowel syndrome and erectile dysfunction.

Product Portfolio

  • Active pharmaceutical ingredients
  • Finished dosage forms
  • Herbal medicines
  • Inhalers
  • Lozenges
  • Animal health

Key Focus Areas

Research & Development

The company‘s R & D focus centers around the following:

  • Formulation & Development Department
  • Analytical Method Development Department
  • Active Pharmaceutical Ingredient Department

The company’s proposed objectives for R&D centre are:

  • To develop and transfer technology for Novel drug Delivery Systems (NDDS)
  • To chemically synthesize niche pharmaceutical products
  • To develop formulations for export markets; Generics for regulated markets and Innovative for non-regulated markets
  • To develop formulations to enable New Drug Application with the Drug Controller of India in the Ministry of Health
  • To develop and validate analytical procedures to support development of bulk drugs and formulations
  • To conduct bio-equivalence studies to assure high level of confidence and meet with time-lines
  • The proposed Aanjaneya R & D centre is located in Mahad, will be spread over an area of 10,000 sq. feet. The R & D facility is in process of being setup in and will be compliant to the Department of Scientific and Industrial Research, Govt. of India, requirements.

Technology Transfer Services

Consulting - Preparation of product and material specifications evaluation of existing production facilities to meet GMP definition of appropriate plant size and technologies

Project Appraisal - Financial and economic evaluations feasibility studies

Engineering - Design of plant layout, basic and detail engineering blue prints for civil engineering works

Plant Supply - Supply of plant equipment and supervision of erection and start up

Commissioning - Overall works supervision and supervision of erection and start up 

Training - Training schemes at Cipla's production facilities and on - the - job training courses 

Operational Management - Production planning and management 

Support - Raw materials management 

Know - How Transfer - Product know - how process know - how new developments. 

Quality Control - Development of analytical method, establishment of quality control guidelines according to GMP and quality control manuals.

Business Focus

The medium term strategy of the company is to continuously globalize the intellectual property assets and enhance value to customers.

In global markets, the company shall retain and enhance cost efficient quality leadership in anti malarial drugs. It is the endeavor of the company to achieve this by resolving complex chemistry challenges, improving process efficiencies, adopting global scale manufacturing and using cost effective market networks throughout South East Asia, Africa and Latin America.

The company’s competitive advantage is in capturing a large portfolio of approvals, backed up by a global standard R&D effort that offers several patented non-infringing processes and intellectual properties, and a cost efficient manufacturing environment complying with USFDA and EU authorities.

The company shall forge alliances with original research companies in the area of custom synthesis. The existing relationships and credibility will help Aanjaneya to acquire a significant part of bulk manufacturing of original research companies into its units.

The corporate plans are to ensure growth through organic and inorganic means, and by adopting strategic joint ventures and alliances. The objective is to maximize the revenues and reduce risks.

The long term growth strategies being put in to action include:

Develop a broad portfolio of DMFs through non-infringing processes and intellectual properties and become a significant player in the generics market, especially in the regulated markets

    Manage cost efficiently in a mega-manufacturing environment approved by USFDA/European regulatory authorities; and in the process, enhance its attractiveness to alliance partners

Emerge as a leading player in global high quality innovative specialty branded generic formulations and domestic brand segments

Leverage the strength in introducing innovative drugs in lozenges forms

Be an integrated player in fast developing herbal drugs segment by introducing range of formulations in Syrups, Lozenges, Tablets Capsules and gels for various therapeutic segments

Facilities 

Bulk Actives - Manufacturing facilities at Mahad MIDC

The company’s API complex in Mahad near Mumbai provides multi-therapeutic product offerings comprising high-end Alkaloids, Quinine Salts, and Veterinary APIs and Cytotoxic API's. Spanning 20,000 sq. mtrs, this facility is a world-class manufacturing complex which can handle complex synthesis and reactions with the highest levels of safety and productivity. The facility has an aggregate reactor capability of over 75 kl with reactors of varied metallurgy including cast alloy and several centrifuges, driers and production equipment. It is worth mentioning that the facility uses complex gases and a high technology hydro-genator system. The facility is also awarded the ISO 14001 (Environment Management System), ISO 9001:2008 and ISO 220000 certifications by BSI. The facilities are UK MHRA & EUGMP compliant.

The company proposes to implement Enterprise Resource Planning (ERP) at both plants and Head Office. Phase I will cover Finance, Supply Chain Management and Human Resource and Phase II will cover Manufacturing and Quality Control. This will manage all the hard data of its business including data on planning, purchase, inventory, manufacture, quality control, shipments, accounting and costing.

Finished Dosages Facility - Perungut Pune

Located in a site area of about 4 acres, the company’s Formulations Complex has facilities for manufacturing various types of dosage forms such as Liquid Syrups, oral tablets, lozenges and Gels in several product categories complying with international standards. It complies with WHO, cGMP, MHRA and TGA norms and has received ISO 9001, ISO 14001 and OHSAS 18001 (Occupational Health and Safety Management System) certifications; adequately reflecting Aanjaneya’s commitment towards quality and safety. Attainment of such standards have also opened the key to gaining footholds in regulated, lucrative markets like the US and EU for the company.

The overall facility and building design ensures the highest standards of aseptic manufacture, in compliance with the relevant Good Manufacturing Practices (GMP). The design of the building with dedicated HVAC systems and stringent controls on personnel and material movements are developed to avoid any cross-contamination of areas. Appropriate measures are taken to ensure that the product is contained within the building and particles do not escape to the external environment. The design incorporates, for this purpose, HEPA filters on air discharged to the external atmosphere and air locks where materials exit and enter, besides garment change protocols for personnel on entry and exit. This facility thus represents an advanced Liquid Filling line, comparable with the best in the world. The facility further reinforces Aanjaneya’s and India’s technical competencies in the global pharmaceutical industry.

Awards & Achievements

Excellence Award - The company’s Chairman Shri Kashi Vishwanathan received the Excellence Award from Former Hon. Dy. Prime Minister of Thailand Korn Dabaraasi at Indo - Thai Economic Cooperation Summit Held in Delhi in April 2009

Business Excellence Award - The company received the Business Excellence Award at World Summit of emerging India in July 2009

Quality Award - The company received the Quality Award from Europe Business Assembly in Vienna in December 2009

WHO GMP Certification - The company facilities have ISO 9001:2008, ISO 14001:2004 & ISO 22000 from BSI Systems and Pune facility has WHO GMP certification

Milestones

  • May 06, 2011 - Aanjaneya Lifecare enters into the capital market with an IPO of 50,00,000 equity shares
  • Jun 28, 2011 - The company receives Certificate of Suitability for two Bulk Drugs
  • Jun 29, 2011 - The company bags order worth Rs 60 crore from new clients
  • Jul 05, 2011 - The company features in the Top 100 of ‘India's Best Companies to Work for’ 2011
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.